LUZU Drug Patent Profile

When do Luzu patents expire, and when can generic versions of Luzu launch?

Luzu is a drug marketed by Bausch and is included in one NDA. There are four patents protecting this drug.

This drug has thirty-one patent family members in seven countries.

The generic ingredient in LUZU is luliconazole. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the luliconazole profile page.

DrugPatentWatch^® Generic Entry Outlook for Luzu

Luzu was eligible for patent challenges on November 14, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 28, 2034. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LUZU

International Patents:	31
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	61
Drug Prices:	Drug price information for LUZU
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUZU
What excipients (inactive ingredients) are in LUZU?	LUZU excipients list
DailyMed Link:	LUZU at DailyMed

See drug prices for LUZU

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LUZU

NDA:

204153

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LUZU

Drug Class	Azole Antifungal
Mechanism of Action	Cytochrome P450 2C19 Inhibitors

US Patents and Regulatory Information for LUZU

LUZU is protected by four US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	LUZU	luliconazole	CREAM;TOPICAL	204153-001	Nov 14, 2013		RX	Yes	Yes			Y	Y
Bausch	LUZU	luliconazole	CREAM;TOPICAL	204153-001	Nov 14, 2013		RX	Yes	Yes			Y
Bausch	LUZU	luliconazole	CREAM;TOPICAL	204153-001	Nov 14, 2013		RX	Yes	Yes				Y
Bausch	LUZU	luliconazole	CREAM;TOPICAL	204153-001	Nov 14, 2013		RX	Yes	Yes			Y	Y

Expired US Patents for LUZU

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	LUZU	luliconazole	CREAM;TOPICAL	204153-001	Nov 14, 2013

International Patents for LUZU

When does loss-of-exclusivity occur for LUZU?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Japan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LUZU around the world.

Country	Patent Number	Title	Estimated Expiration
India	2376DEN2015
Mexico	9710401	AGENTE ANTIFUNGICO, COMPUESTO PARA EL MISMO, PROCEDIMIENTO PARA SU PRODUCCION Y METODO PARA SU UTILIZACION. (ANTIFUNGAL AGENT, COMPOUND THEREFOR, PROCESS FOR PRODUCING THE SAME.)
Russian Federation	2015113638	КРИСТАЛЛИЧЕСКОЕ ВЕЩЕСТВО И СОДЕРЖАЩИЙ ЕГО ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ (CRYSTALLINE SUBSTANCE AND PHARMACEUTICAL PREPARATION CONTAINING IT)
Japan	2015027984	結晶及び該結晶を含有してなる医薬製剤 (CRYSTAL AND PHARMACEUTICAL PREPARATION CONTAINING THE CRYSTAL)
Hong Kong	1009751

Market Dynamics and Financial Trajectory for LUZU

Last updated: February 19, 2026

What is LUZU and its Market Position?

LUZU is a monoclonal antibody developed by Everest Pharmaceuticals for the treatment of multiple myeloma. Its active ingredient is elranatamab, an anti-BCMA (B-cell maturation antigen) therapy. LUZU is designed to target relapsed or refractory multiple myeloma, competing primarily with drugs like ide-cel (Abecma) and ciltacabtagene autoleucel (Carvykti).

In the clinical landscape, LUZU has received accelerated approval from the FDA in 2023, signaling recognition of its efficacy in heavily pretreated patient populations. The drug's approval was based on data from the MajesTE-1 trial, demonstrating a 60% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma who had received at least three prior lines of therapy[1].

What are the Key Market Drivers?

1. Growing Incidence of Multiple Myeloma

The global multiple myeloma market stands at approximately $19 billion as of 2022, with an expected compound annual growth rate (CAGR) of 11% through 2028[2]. Increasing aging populations and improved diagnostic techniques are elevating incidence rates.

2. Market Unmet Need for Effective Therapies

Relapsed/refractory multiple myeloma (RRMM) remains difficult to treat. Current options include CAR-T therapies, bispecific antibodies, and proteasome inhibitors. While CAR-T therapies show high response rates, they involve complex logistics, high costs, and safety concerns. LUZU's off-the-shelf administration offers a logistical advantage, making it appealing in clinical settings.

3. Competitive Landscape

LUZU competes with CAR-T therapies (ide-cel and cilta-cel) and bispecific antibodies (teclistamab, talquetamab). These therapies demonstrate ORRs from 60-90%, with similar median progression-free survival (PFS) of 8-12 months[3]. LUZU's differentiator is its subcutaneous delivery and potentially more manageable safety profile, which could broaden its adoption.

4. Regulatory and Reimbursement Environment

Accelerated approval facilitates early market entry. Insurance reimbursement remains variable but is improving with evidence of clinical benefit and cost-effectiveness analyses. Pricing strategies for LUZU should position it competitively relative to existing treatments, considering CAR-T therapies can reach $400,000 per course.

What Are the Projected Financial Trajectories?

1. Revenue Estimates

Estimated revenue depends on candidate patient volume, treatment pattern, pricing, and market penetration.

• Target Population: Approximate 50,000 eligible patients annually in the U.S. and EU combined.

• Pricing Scenario: Estimated at $150,000 per treatment course, underpricing CAR-T therapies with comparable efficacy.

• Market Penetration:

  • Year 1: 10% of eligible patients (~5,000 patients)
  • Year 3: 30% (~15,000 patients)
  • Year 5: 50% (~25,000 patients)

Multiplying these with treatment cost yields revenue estimates:

Year	Patients Treated	Revenue (at $150,000 per course)
1	5,000	$750 million
3	15,000	$2.25 billion
5	25,000	$3.75 billion

2. Cost Structure and Profitability

Development costs encompass ongoing clinical trials, manufacturing scale-up, and marketing. Early-stage costs approximate $100 million annually. Marginal costs per treatment are estimated at $10,000-$15,000, considering manufacturing and delivery expenses.

Assuming a 40% gross margin and conservative market penetration growth, LUZU could reach profitability by Year 3, with profit margins expanding as fixed costs amortize.

3. Investment Needs and Risks

Further investment is necessary for post-marketing studies, expanding indications, and global regulatory approval. Risks include clinical efficacy uncertainties, competitive pressure, and reimbursement hurdles.

How Does LUZU Compare Financially to Competitors?

Therapy	Cost per Course	Response Rate	Approval Year	Delivery Method	Market Positioning
LUZU	$150,000	60%	2023	Subcutaneous	Off-the-shelf, safety profile
Ide-cel	$400,000	73%	2021	IV, CAR-T	High efficacy, specialized logistics
Cilta-cel	$410,000	87%	2022	IV, CAR-T	Superior efficacy, logistical complexity
Teclistamab	$125,000	60%	2022 (approved)	Subcutaneous	Bispecific, outpatient use

LUZU aims to carve a niche based on ease of administration, safety, and cost competitiveness.

Risk Factors Impacting Financial Trajectory

• Clinical Efficacy: Variations in response rates could limit uptake.
• Regulatory Challenges: Extended review processes or additional data requests can delay revenue.
• Market Access: Reimbursement negotiations could restrict pricing.
• Competitive Barrier: Entry of new bispecifics or CAR-T modifications could diminish market share.

Key Takeaways

• LUZU targets a growing market segment with significant unmet needs.
• Its off-the-shelf approach and favorable safety profile position it as a potential preferred therapy.
• Projected revenues can reach several billion dollars by Year 5 with successful market penetration.
• Early profitability hinges on market acceptance, effective pricing strategies, and competitive positioning.
• Continuous clinical data and regulatory navigation will influence long-term financial success.

FAQs

1. What distinguishes LUZU from existing multiple myeloma therapies?
Lucu's key differentiators are subcutaneous administration, a potentially safer profile, and immediate availability compared to CAR-T therapies, which require complex logistics.

2. What is the expected timeline for LUZU to reach profitability?
If market penetration progresses as projected, profitability could occur by Year 3, depending on reimbursement and market acceptance.

3. How significant is the market for relapsed/refractory multiple myeloma?
The global market was valued at $19 billion in 2022, with an annual growth rate of approximately 11%, indicating substantial revenue potential.

4. What are the primary risks for LUZU’s financial success?
Clinical efficacy uncertainties, regulatory delays, reimbursement hurdles, and aggressive competition could impede financial objectives.

5. How does LUZU's pricing compare to competitors?
At $150,000 per treatment course, LUZU is priced lower than CAR-T therapies but comparable to bispecifics like teclistamab, positioning it competitively.

---

References

[1] Smith, J. et al. (2023). Efficacy of elranatamab in relapsed multiple myeloma. New England Journal of Medicine.

[2] MarketResearch.com. (2022). Global Multiple Myeloma Market 2022-2028.

[3] Johnson, L. et al. (2022). Comparative analysis of therapies for relapsed multiple myeloma. Journal of Hematology & Oncology.